Non Small Cell Lung Cancer - Pharma

Relevant Publications

Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomes.

Issue Release: 2024

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

Issue Release: 2024

Tanreqing injection inhibits stemness and enhances sensitivity of non-small cell lung cancer models to gefitinib through ROS/STAT3 signaling pathway.

Issue Release: 2024

When to Consider Invasive Lymph Node Staging in Non-Small-Cell Lung Cancer? A Novel Scoring System Utilising Metabolic Parameters in 18F-FDG PET/CT.

Issue Release: 2024

Exploring the biology of ctDNA release in colorectal cancer.

Issue Release: 2024

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC.

Issue Release: 2024

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.

Issue Release: 2024

Distinct roles and molecular mechanisms of nicotine and benzo(a)pyrene in ferroptosis of lung adenocarcinoma and lung squamous cell carcinoma.

Issue Release: 2024

Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).

Issue Release: 2024

Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer.

Issue Release: 2024

Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

Issue Release: 2024

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG mutation in China and the United States.

Issue Release: 2024

Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer.

Issue Release: 2024

[Effect of glucocorticoids on the efficacy of non-small cell lung cancer patients treated with immune-checkpoint inhibitors].

Issue Release: 2024

Clustered Circulating Tumor Cells as a Predictor of Adjuvant-chemotherapy Efficacy in Lung Cancer.

Issue Release: 2024

Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.

Issue Release: 2024

Safety and Efficacy Outcomes of Early Cessation of Anti-PD1 Therapy in Patients 80 Years or Older: A Retrospective Cohort Study.

Issue Release: 2024

New vision of HookEfficientNet deep neural network: Intelligent histopathological recognition system of non-small cell lung cancer.

Issue Release: 2024

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.

Issue Release: 2024

Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.

Issue Release: 2024

What are Contract Research Organizations (CROs)?

How Can Technology Aid in Patient Education?

What Causes Adverse Drug Events?

What are the Phases of Clinical Trials?

Why is Generic Competition Important?

How Do Collaborative Care Models Work?

How are ADEs Detected and Reported?

Why is Geriatric Care Important?

What are the Key Cellular Stress Pathways?

What Challenges Do Pharmacists Face?

Non Small Cell Lung Cancer - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics